

RealRate

PHARMACEUTICAL 2020











RealRate

PHARMACEUTICAL 2020

XBiotech Inc. Rank 1 of 358



The relative strengths and weaknesses of XBiotech Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of XBiotech Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 239% points. The greatest weakness of XBiotech Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 29% points.

The company's Economic Capital Ratio, given in the ranking table, is 448%, being 412% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	716,263
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	60,190
Liabilities, Non-Current	0
Other Assets	75,443
Other Compr. Net Income	149
Other Expenses	49,824
Other Liabilities	1,056
Other Net Income	749,686
Other Revenues	0
Property and Equipment	25,171
Research and Development	24,090
Selling, General and Administrative Expense	7,143

Output Variable	Value in 1000 USD
Assets	816,877
Liabilities	61,246
Expenses	81,057
Revenues	0
Stockholders Equity	755,631
Net Income	668,629
Comprehensive Net Income	668,704
Economic Capital Ratio	448%

